



Advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.

Booth #2927

MassBio.org

BioTech Daily News

An independent publication not affiliated with any other organization

Tuesday
June 16, 2015

1st EDITION

Philadelphia • FREE

Introducing Adare Pharmaceuticals

Article Courtesy of Adare Pharmaceuticals

On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company's new name is Adare Pharmaceuticals.

Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.

Building upon our legacy, we strive to reshape medicines tailored to the needs of the evolving global health care market. Through internal

ADARE
Pharmaceuticals™

continued on page 45

Therapure Biomanufacturing Repeats as Multiple Winner in CMO Leadership Awards

In a competition that uses pharma selection criteria combined with peer feedback to identify the industry's very best contract manufacturing partners, Therapure Biomanufacturing, a global contract development and manufacturing organization (CDMO), has once again been recognized as a leader in the quality, reliability, productivity and regulatory categories. This is Therapure Biomanufacturing's fourth year as a multiple winner



continued on page 45

The World's First Medical Grade Carbon Nanotube

Q: So tell us a little about your company.

A: We manufacture the world's first medical grade carbon nanotube called Medical Grade Molecular Rebar or MGMR. Our material is ideal for use in medical applications such as targeted drug delivery and transdermal drug delivery. The potential to impact the lives of millions of patients is so great that we're making a selection of R&D kits immediately available to researchers. These kits are specifically tailored to meet laboratory



continued on page 45

Selecting the "Right" Partner for Contract Drug Development and Manufacturing Requires the "Right" Information

For many small biotechnology firms the resources and expertise required to bring a compound to the marketplace are often very limited. For organizations that decide

to partner with a CDMO making the right choice is critical. The following criteria may help simplify an otherwise daunting task.



Look for Experience
Ask the prospective partner such

continued on page 45

Cyto-Mine Single Cell Analysis and Monoclonality Assurance System: An Automated Platform Delivering High-Throughput Novel Assays on Single Cells and Their Interactions



Sphere Fluidics is an established innovative Life Sciences company that has developed a unique technology platform for the generation, fusing, analysis, sorting and retrieval of small volumes (picolitre to nanolitre) of aqueous

continued on page 26

Finding the Most Effective Treatment for Each Individual Cancer Patient

Helomics believes that each patient is unique, and the cancer treatment should be too. The company's in-depth approach to characterizing patients' live and archived cancer cells allows physicians to create personal tumor profiles to individualize treatment options for their patients

"Several factors shape the way a cancer patient will respond to cancer treatment," said Neil J. Campbell, Helomics President and CEO. "A chemotherapy that works well on one patient



continued on page 45

Accelerating Biomedical Research, One Egg at a Time

Immune Biosolutions is an innovative Canadian antibody producer for the biomedical, biotech and pharmaceutical industries. Its dedicated team focuses on creating high-quality polyclonal and recombinant chicken antibodies as molecular tools, nutraceuticals and antibody-based drugs.

Birth of Stellar Custom Antibodies

The Nebula Antibody Platform enables an incremental customer-oriented antibody development from biomarker discovery to therapeutics taking advantage of the unique



continued on page 47

Bridging Drug Discovery Through Commercialization

Article Courtesy of Lyophilization Technology, Inc.

Lyophilization Technology, Inc. (LTI) is a Contract Development and Manufacturing Organization (CDMO) focused on all aspects of lyophilization for preparation of health care products.

Clients leverage on our abilities for bringing new products to the clinic and implementing improvements for current products. LTI is recognized as an industry leader with unparalleled capabilities in product development, process engineering, clinical



continued on page 47

WHEATON Highlights Unique Products at BIO 2015, Providing Purpose-Built Solutions for the Biotech and Pharmaceutical Industries

Visit Booth #3103 to Learn More about WHEATON

Value-Added Products Designed to Address Biotech and Pharma's Special Needs, Including High Recovery Vials and DURAN Ultra-Pure Glassware



WHEATON, a provider of high

continued on page 5

Booth #3727.

Susanne Resatz, Ph.D.

President Vetter Development Services USA, Inc.

Susanne Resatz, Ph.D., President of Vetter Development Services USA, Inc., heads Vetter's clinical manufacturing facility in suburban Chicago, Illinois. Vetter is an independent international contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with a clientele that includes the world's leading pharmaceutical and biotechnology companies. Its Chicago facility is the company's first U.S. site, and provides development support and aseptic manufacturing for pre-clinical through Phase IIb injectables, primarily complex biologics.

Dr. Resatz relocated from Germany to the United States in 2010, and was among the first employees to help establish the new state-of-the-art facility, known as VDS Chicago and located at the Illinois Science + Technology Park in Skokie, Illinois. Here, she was responsible for the Process Development

and Manufacturing function, which included monitoring the pharmaceutical process from the beginning of a customer's sample production to visually inspecting the finished product. In addition to actively developing and implementing customer projects, Resatz has been directly involved in training newly hired U.S. staff on pharmaceutical technology processes. The facility, which became fully operational in 2011, currently operates with a growing staff of 50, and has collaborated with biopharmaceutical clients from the U.S., as well as Europe, Asia and the Middle East, with treatments under development for cancer, muscular dystrophy, dwarfism and other conditions.

In 2002, Resatz earned a master's degree with a major in applied mathematics from Vienna University of Technology, and a doctoral degree in the field of computational neuroscience and biomedical engineering from Vienna University of Technology in 2005.

Resatz is a frequent presenter at biopharmaceutical industry forums on aseptic manufacturing and other topics.